Ultragenyx Pharmaceutical (RARE) Cash & Current Investments (2013 - 2026)

Ultragenyx Pharmaceutical (RARE) has 14 years of Cash & Current Investments data on file, last reported at $413.0 million in Q1 2026.

• On a quarterly basis, Cash & Current Investments fell 16.46% year-over-year to $413.0 million in Q1 2026; TTM through Mar 2026 was $413.0 million, a 16.46% decrease from a year earlier, with the FY2025 full-year figure at $680.0 million, up 11.48% from the prior year.
• Cash & Current Investments for Q1 2026 stood at $413.0 million, down from $680.0 million in the prior quarter.
• Over the last five years, Cash & Current Investments for RARE reached as high as $888.7 million in Q3 2022 and fell as low as $135.8 million in Q4 2022.
• Historically, Cash & Current Investments has averaged $524.3 million across 5 years, with a median of $542.8 million in 2022.
• Across the five-year window, Cash & Current Investments slumped 58.37% in 2022 and surged 180.84% in 2024, its largest moves.
• Year by year, Cash & Current Investments stood at $135.8 million in 2022, then soared by 60.0% to $217.2 million in 2023, then jumped by 180.84% to $610.0 million in 2024, then advanced by 11.48% to $680.0 million in 2025, then tumbled by 39.26% to $413.0 million in 2026.
• Per Business Quant data, the three most recent Cash & Current Investments figures were $413.0 million in Q1 2026, $680.0 million in Q4 2025, and $425.2 million in Q3 2025.